David Boles

Cooley advised Alvotech Holdings, a global biopharmaceutical company focused on the development and manufacturing of biosimilar medicines for patients worldwide, on its agreement to merge with special purpose acquisition company (SPAC) Oaktree Acquisition Corp. II. Lawyers Michal Berkner, Div Gupta, Nicolas Dumont and Jarrett Burks led the Cooley team advising Alvotech.

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Cooley advised SimilarWeb on its $176 million initial public offering of 8,000,000 ordinary shares. SimilarWeb, whose securities now trade on the New York Stock Exchange under the symbol SMWB, is a developer of a digital market intelligence platform. Partners Nicole Brookshire, Stephane Levy and David Boles led the Cooley team.

Cooley advised Pharming Group on its direct listing of 899,802 American depositary shares. Pharming Group, whose shares are now listed on the Nasdaq Global Market under the symbol PHAR, also trades on Euronext Amsterdam Market under the symbol PHARM. Pharming Group is a commercial-stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. Partner David Boles, Eric Blanchard and David Boles led the Cooley team.